Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

efocipegtrutide

A long-acting glucagon/gastric inhibitory peptide (GIP)/glucagon-like peptide-1 (GLP-1) triple receptor agonist conjugated with constant region of human immunoglobulin via a non-peptidyl flexible linker, with potential antihyperglycemic, anti-inflammatory and anti-fibrotic activities. Upon administration, efocipegtrutide binds to and activates multiple incretin receptors, including glucagon receptor (GCGR), GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), which may decrease liver fat accumulation, inflammation and fibrogenesis, and normalize blood glucose levels.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:HM 15211
HM-15211
HM15211
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search